Latest period
$10.83B
YoY change
-1.3%
5Y CAGR
-4.3%
Peak year (2020)
$13.93B
Latest annual
$11.18B
Total Liabilities history chart for Biogen (BIIB) from 1985 to 2025
Latest: $11.18B
Total Liabilities growth chart for Biogen (BIIB) from 1985 to 2025
Latest: -1.3%
Total Liabilities history table for Biogen (BIIB) from 1985 to 2025
| 2025 | $11.18B | -1.3% | −$150.60M | ||
| 2024 | $11.33B | -5.9% | −$712.10M | ||
| 2023 | $12.05B | +7.9% | +$879.70M | ||
| 2022 | $11.17B | -13.6% | −$1.75B | ||
| 2021 | $12.92B | -7.3% | −$1.02B | ||
| 2020 | $13.93B | +0.3% | +$37.60M | ||
| 2019 | $13.90B | +13.4% | +$1.64B | ||
| 2018 | $12.26B | +10.9% | +$1.20B | ||
| 2017 | $11.05B | +2.8% | +$306.30M | ||
| 2016 | $10.75B | +6.1% | +$618.30M | ||
| 2015 | $10.13B | +189.2% | +$6.63B | ||
| 2014 | $3.50B | +8.0% | +$260.02M | ||
| 2013 | $3.24B | +2.4% | +$76.17M | ||
| 2012 | $3.17B | +20.7% | +$543.71M | ||
| 2011 | $2.62B | -0.8% | −$20.43M | ||
| 2010 | $2.64B | +15.4% | +$353.08M | ||
| 2009 | $2.29B | -14.3% | −$382.94M | ||
| 2008 | $2.67B | -13.6% | −$421.61M | ||
| 2007 | $3.09B | +120.6% | +$1.69B | ||
| 2006 | $1.40B | -4.0% | −$58.04M | ||
| 2005 | $1.46B | -37.5% | −$878.29M | ||
| 2004 | $2.34B | -4.5% | −$111.26M | ||
| 2003 | $2.45B | +495.4% | +$2.04B | ||
| 2002 | $411.57M | +10.6% | +$39.35M | ||
| 2001 | $372.21M | +14.4% | +$46.76M | ||
| 2000 | $325.45M | +9.1% | +$27.01M | ||
| 1999 | $298.44M | +44.8% | +$92.34M | ||
| 1998 | $206.10M | -25.7% | −$71.43M | ||
| 1997 | $277.53M | +84.8% | +$127.33M | ||
| 1996 | $150.20M | +74.2% | +$63.98M | ||
| 1995 | $86.22M | +79.9% | +$38.29M | ||
| 1994 | $47.93M | +50.7% | +$16.13M | ||
| 1993 | $31.80M | +21.4% | +$5.60M | ||
| 1992 | $26.20M | +85.8% | +$12.10M | ||
| 1991 | $14.10M | +10.2% | +$1.30M | ||
| 1990 | $12.80M | +113.3% | +$6.80M | ||
| 1989 | $6.00M | -53.5% | −$6.90M | ||
| 1988 | $12.90M | +0.8% | +$100.00K | ||
| 1987 | $12.80M | +10.3% | +$1.20M | ||
| 1986 | $11.60M | +6.4% | +$700.00K | ||
| 1985 | $10.90M | — | — |
- 2025$11.18B-1.3%
- 2024$11.33B-5.9%
- 2023$12.05B+7.9%
- 2022$11.17B-13.6%
- 2021$12.92B-7.3%
- 2020$13.93B+0.3%
- 2019$13.90B+13.4%
- 2018$12.26B+10.9%
- 2017$11.05B+2.8%
- 2016$10.75B+6.1%
- 2015$10.13B+189.2%
- 2014$3.50B+8.0%
- 2013$3.24B+2.4%
- 2012$3.17B+20.7%
- 2011$2.62B-0.8%
- 2010$2.64B+15.4%
- 2009$2.29B-14.3%
- 2008$2.67B-13.6%
- 2007$3.09B+120.6%
- 2006$1.40B-4.0%
- 2005$1.46B-37.5%
- 2004$2.34B-4.5%
- 2003$2.45B+495.4%
- 2002$411.57M+10.6%
- 2001$372.21M+14.4%
- 2000$325.45M+9.1%
- 1999$298.44M+44.8%
- 1998$206.10M-25.7%
- 1997$277.53M+84.8%
- 1996$150.20M+74.2%
- 1995$86.22M+79.9%
- 1994$47.93M+50.7%
- 1993$31.80M+21.4%
- 1992$26.20M+85.8%
- 1991$14.10M+10.2%
- 1990$12.80M+113.3%
- 1989$6.00M-53.5%
- 1988$12.90M+0.8%
- 1987$12.80M+10.3%
- 1986$11.60M+6.4%
- 1985$10.90M—
Total Liabilities values are taken from Biogen's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Biogen (BIIB)
According to Biogen's latest reported financial statements, the company's latest reported total liabilities is $10.83B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
Biogen (BIIB) most recent annual total liabilities stands at $11.18B (2025) – edged down 1.3% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Biogen total liabilities compounded at -4.3% per year, with a net decline across the window.
$13.93B stands as the all-time-high annual total liabilities, posted in 2020, against a low of $6.00M during 1989.
Biogen Total Liabilities by Year
Biogen Total Liabilities 2025: $11.18B
2025's total liabilities for Biogen came in at $11.18B, edged down 1.3% below 2024.
Biogen Total Liabilities 2024: $11.33B
Biogen posted total liabilities of $11.33B in 2024, declined 5.9% below 2023.
Biogen Total Liabilities 2023: $12.05B
In 2023, Biogen reported total liabilities of $12.05B, grew 7.9% from 2022.
Biogen Total Liabilities 2022: $11.17B
Biogen total liabilities in 2022 was $11.17B, declined 13.6% below 2021.
Biogen Total Liabilities 2021: $12.92B
Biogen total liabilities in 2021 was $12.92B.
See more financial history for Biogen (BIIB).
Sector peers by Total Liabilities
Healthcare peers of Biogen (BIIB), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Biogen (BIIB) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation